156 related articles for article (PubMed ID: 19252761)
1. Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
Voorzanger-Rousselot N; Journe F; Doriath V; Body JJ; Garnero P
Calcif Tissue Int; 2009 May; 84(5):348-54. PubMed ID: 19252761
[TBL] [Abstract][Full Text] [Related]
2. Increased Dickkopf-1 expression in breast cancer bone metastases.
Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
4. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
6. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.
Voorzanger-Rousselot N; Juillet F; Mareau E; Zimmermann J; Kalebic T; Garnero P
Br J Cancer; 2006 Aug; 95(4):506-14. PubMed ID: 16880790
[TBL] [Abstract][Full Text] [Related]
7. [Bone turnover markers in the detection of bone metastases in primary lung cancer].
Kong QQ; Tu CQ; Dou QY; Wang JP; Sun TW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):397-9. PubMed ID: 15931879
[TBL] [Abstract][Full Text] [Related]
8. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
9. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
11. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
12. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
13. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
[TBL] [Abstract][Full Text] [Related]
14. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
15. Serum tumor markers in skeletal metastasis.
Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
[TBL] [Abstract][Full Text] [Related]
16. Serum ostase in the follow-up of breast cancer patients.
Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
[TBL] [Abstract][Full Text] [Related]
17. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women.
Kim BJ; Yu YM; Kim EN; Chung YE; Koh JM; Kim GS
Clin Endocrinol (Oxf); 2007 Jul; 67(1):152-8. PubMed ID: 17466002
[TBL] [Abstract][Full Text] [Related]
18. Markers of bone turnover do not predict bone metastases in breast cancer.
Seibel MJ; Koeller M; Van der Velden B; Diel I
Clin Lab; 2002; 48(11-12):583-8. PubMed ID: 12465741
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
[TBL] [Abstract][Full Text] [Related]
20. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]